Literature DB >> 28246687

[Multimorbidity management and the physician's daily clinical dilemma].

E Battegay1,2,3, M Cheetham4,5,6, B M Holzer4,5,6, A Nowak4, D Schmidt4,5,6, S Rampini4.   

Abstract

About 20-25% of all persons and about 90% of all patients who are acutely hospitalized in internal medicine departments have multiple acute or chronic diseases. They are multimorbid. The encounter with multimorbid patients has become the most common situation in the health care system. Theoretically, multimorbidity results in an innumerable potential disease constellations. In addition, the likelihood of interactions between diseases (disease-disease interactions, DDI) and the complexity increases overproportionately with each additional disease. However, multimorbidity often occurs in typical diadic, triadic, or higher characteristic combinations, in "disease clusters", e. g., vascular risk factors, heart and lung diseases, Frailty and dementia, psychiatric and somatic disorders. Such combinations lead to a worsening of the overall prognosis. In addition, DDIs are often difficult to treat or are life-threatening. Examples of DDIs include the following: anticoagulation and simultaneous severe bleeding, pain treatment and hypertension or renal insufficiency, depression and reduced medication adherence, chronic obstructive pulmonary disease and depression, Frailty and neurodepressant drugs and frequent falls, and combined psychiatric and somatic disorders. Such DDIs are common. Nevertheless, there are few studies and clinical guidelines that address these issues. The care of multimorbid patients is, therefore, heavily reliant upon guidelines developed mostly for single diseases. However, multimorbidity and serious DDIs are usually not addressed in these. Clinical guidelines can thus inadvertently jeopardize the safety of persons suffering from multiple diseases. In addition, stressful dilemmas arise for physicians encountering DDIs because of difficult treatment decisions.

Entities:  

Keywords:  Anticoagulants; Disease–disease interactions; Hemorrhage; Hypertension; Pain, drug therapy

Mesh:

Year:  2017        PMID: 28246687     DOI: 10.1007/s00108-017-0200-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  21 in total

1.  Prevalence of multimorbidity in medical inpatients.

Authors:  Florian Schneider; Vladimir Kaplan; Roksana Rodak; Edouard Battegay; Barbara Holzer
Journal:  Swiss Med Wkly       Date:  2012-03-09       Impact factor: 2.193

2.  Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis.

Authors:  Xiao-xia Liu; Xiao-ming Zhu; Qing Miao; Hong-ying Ye; Zhao-yun Zhang; Yi-Ming Li
Journal:  Ann Nutr Metab       Date:  2014-11-14       Impact factor: 3.374

Review 3.  A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects.

Authors:  Emma J Turtle; James W Dear; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

4.  Functional impairment in COPD patients: the impact of anxiety and depression.

Authors:  H F Kim; M E Kunik; V A Molinari; S L Hillman; S Lalani; C A Orengo; N J Petersen; Z Nahas; S Goodnight-White
Journal:  Psychosomatics       Date:  2000 Nov-Dec       Impact factor: 2.386

Review 5.  Anxiety and depression-Important psychological comorbidities of COPD.

Authors:  Marsus I Pumar; Curt R Gray; James R Walsh; Ian A Yang; Tricia A Rolls; Donna L Ward
Journal:  J Thorac Dis       Date:  2014-11       Impact factor: 2.895

6.  Patterns of chronic multimorbidity in the elderly population.

Authors:  Alessandra Marengoni; Debora Rizzuto; Hui-Xin Wang; Bengt Winblad; Laura Fratiglioni
Journal:  J Am Geriatr Soc       Date:  2009-02       Impact factor: 5.562

7.  Current guidelines poorly address multimorbidity: pilot of the interaction matrix method.

Authors:  Christiane Muth; Hanna Kirchner; Marjan van den Akker; Martin Scherer; Paul P Glasziou
Journal:  J Clin Epidemiol       Date:  2014-09-10       Impact factor: 6.437

8.  Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study.

Authors:  Karen Barnett; Stewart W Mercer; Michael Norbury; Graham Watt; Sally Wyke; Bruce Guthrie
Journal:  Lancet       Date:  2012-05-10       Impact factor: 79.321

9.  Tracing the decision-making process of physicians with a Decision Process Matrix.

Authors:  Daniel Hausmann; Cristina Zulian; Edouard Battegay; Lukas Zimmerli
Journal:  BMC Med Inform Decis Mak       Date:  2016-10-18       Impact factor: 2.796

10.  The multimorbidity interaction severity index (MISI): A proof of concept study.

Authors:  Dimitri Gassmann; Marcus Cheetham; Klarissa Siebenhuener; Barbara M Holzer; Claudine Meindl-Fridez; Florian F Hildenbrand; Vanessa Virgini; Mike Martin; Edouard Battegay
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.817

View more
  4 in total

1.  [Does multimorbidity in older psychiatric patients lead to higher transfer rates between psychiatric and somatic departments?]

Authors:  Tilman Wetterling; Klaus Junghanns
Journal:  Z Gerontol Geriatr       Date:  2018-07-20       Impact factor: 1.281

Review 2.  Multimorbidity and cardiovascular disease: a perspective on low- and middle-income countries.

Authors:  Friedrich Thienemann; Ntobeko A B Ntusi; Edouard Battegay; Beatrice U Mueller; Marcus Cheetham
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

3.  Synthetic consortia of nanobody-coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis-associated diseases and co-morbidities.

Authors:  Kenneth Timmis; James Kenneth Timmis; Harald Brüssow; Luis Ángel Fernández
Journal:  Microb Biotechnol       Date:  2019-01       Impact factor: 5.813

4.  Comorbidities Associated with Worse Outcomes Among Inpatients Admitted for Acute Gastrointestinal Bleeding.

Authors:  K Siebenhüner; J Blaser; A Nowak; M Cheetham; B U Mueller; E Battegay; P E Beeler
Journal:  Dig Dis Sci       Date:  2021-08-07       Impact factor: 3.487

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.